Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Hallmarks of aging
Research brief

TAOK1 overexpression reduced kidney injury after ischemia-reperfusion in aged mice

In aged mice, the protein TAOK1 was lower in kidneys. Raising TAOK1 reduced kidney injury, inflammation and fibrosis after interrupted blood flow, alongside more mitophagy via the STK3/BNIP3 pathway. This is animal and cell research, not a human treatment. [1]

Automatic summary · not editorially reviewed

The key findings

  1. TAOK1 expression was significantly downregulated in the kidneys of aged mice. [1]

  2. Overexpressing TAOK1 in aged mice reduced injury-induced kidney dysfunction, tubular damage, inflammation, NET formation and fibrosis. [1]

  3. The authors conclude TAOK1 protects aged mice against renal ischemia-reperfusion injury by promoting mitophagy via STK3/BNIP3. [1]

The source at a glance

Study type / format
Preclinical animal and cell study (abstract).
Population / context
Aged (23–24 months) C57BL/6 mice and primary renal tubular cells from aged mice.
Summary based on
Study abstract
Original publication
October 20, 2026

Aged mice, TAOK1 and kidney injury

Older people have more and more severe acute kidney injury, but the molecular reasons are poorly understood. This study asked whether the protein TAOK1 plays a role in age-related kidney injury, focusing on mitophagy — the cell's recycling of damaged mitochondria. The work used aged mice and cells from aged mice, not humans.

Supporting source [1]

Interrupted blood flow plus TAOK1 in aged mice

Aged mice (23–24 months) underwent renal ischemia-reperfusion injury, meaning blood flow to the kidney was interrupted and then restored. TAOK1 was overexpressed in these mice. The researchers assessed kidney function, tissue changes, inflammation, neutrophil extracellular trap formation and fibrosis, and examined the STK3/BNIP3 pathway and mitophagy. In cells from aged mouse kidneys, TAOK1 was knocked down before low-oxygen and reoxygenation stress.

Supporting source [1]

Less damage with more TAOK1 in aged mice

TAOK1 was significantly lower in kidneys of aged mice. Overexpressing TAOK1 lessened injury-induced kidney dysfunction, tubular damage, inflammation, neutrophil extracellular trap formation and fibrosis. It also activated the STK3/BNIP3 pathway and increased mitophagy markers. Knocking down TAOK1 in aged mouse kidney cells worsened cell injury and apoptosis and suppressed this pathway. The authors suggest the age-related decline in TAOK1 may contribute to greater susceptibility and call it a potential target — an association in animals, not proven cause or human benefit.

Supporting source [1]

How to interpret this

Abstract only; the full text was not reviewed. Findings come from aged mice and mouse kidney cells, not humans. The abstract reports no sample sizes, follow-up or effect sizes, and the proposed therapeutic target is not tested in people.

Based on the study abstract; the full paper, tables and supplementary data were not reviewed.

Source & supporting passages

[1]
TAOK1 Protects against Renal Ischemia-Reperfusion Injury in Aged Mice through the STK3/BNIP3 Mitophagy Pathway.

Li Z, Chen H, Xia C, Hu S, Ye L, Fu L, Ye Q. · europepmc.org · October 20, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    TAOK1 expression was significantly downregulated in the
  2. Finding 2 ↑

    ameliorated IRI-induced renal dysfunction, tubular damage, inflammation
  3. Finding 3 ↑

    TAOK1 protects against renal IRI in aged

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…